CONTRIBUTIONS OF FLOW CROSS MATCH (FXM) RESULTS AND DONOR SPECIFIC ANTIBODY (DSA) MEASUREMENTS TO ANTIBODY MEDIATED REJECTION (AMR) IN DONOR SENSITIZED KIDNEY TRANSPLANTS

2010 ◽  
Vol 90 ◽  
pp. 377
Author(s):  
T. B. Dunn ◽  
O. Ozturk ◽  
H. Noreen ◽  
D. Maurer ◽  
R. Bray ◽  
...  
Nephron ◽  
2020 ◽  
pp. 1-5
Author(s):  
Takahiro Tsuji ◽  
Sari Iwasaki ◽  
Keishi Makita ◽  
Teppei Imamoto ◽  
Naomichi Ishidate ◽  
...  

<b><i>Aim:</i></b> Chronic active antibody-mediated rejection (CAABMR) is an important cause of late-stage renal allograft loss. Early inflammatory events such as acute rejection and infection after transplantation are considered to be the risk factors of de novo donor-specific antibody (dnDSA) production. In this study, we investigated the relationship between pre­disposing T-cell-mediated rejection and dnDSA-positive CAABMR. <b><i>Methods:</i></b> We recruited 365 patients who underwent ABO-compatible renal transplantation at our hospital. Among them, 16 patients diagnosed as having dnDSA-positive CAABMR were designated as a CAABMR group, and 38 randomly selected patients were designated as a control group. All biopsies from 1 month after transplantation were included in the study. The presence or absence of borderline changes (BLCs), acute T-cell-mediated rejection (ATMR), microvascular inflammation (MVI), and C4d positive on peritubular capillaries (C4d-P) was examined. <b><i>Results:</i></b> In the CAABMR group, BLC/ATMR was found in 12 cases (75%), and the mean duration until appearance of BLC/ATMR was 282.7 ± 328.7 days. C4d-P was found in 11 cases (68.8%), and the mean duration until its appearance was 1,432 ± 1,307 days. MVI was found in all cases, and the mean duration until its appearance was 1,333 ± 1,126 days. The mean duration until diagnosis of CAABMR was 2,268 ± 1,191 days. In the control group, BLC/ATMR was found in 13 cases (34.2%), and the mean duration until the appearance of BLC/ATMR was 173.1 ± 170.4 days. C4d-P was found in 2 cases (5.3%), and the durations until its appearance were 748 and 1,881 days. No cases of MVI were found in the control group. The frequency of BLC/ATMR was significantly higher in the CAABMR group (<i>p</i> &#x3c; 0.01). <b><i>Conclusion:</i></b> Preceding BLC/ATMR is associated with the development of CAABMR with dnDSA.


2016 ◽  
Vol 77 (11) ◽  
pp. 1076-1083 ◽  
Author(s):  
Stéphanie Malard-Castagnet ◽  
Emilie Dugast ◽  
Nicolas Degauque ◽  
Annaïck Pallier ◽  
Jean Paul Soulillou ◽  
...  

2016 ◽  
Vol 16 (4) ◽  
pp. 1216-1228 ◽  
Author(s):  
A. Roux ◽  
I. Bendib Le Lan ◽  
S. Holifanjaniaina ◽  
K. A. Thomas ◽  
A. M. Hamid ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
José M. Arreola-Guerra ◽  
Natalia Castelán ◽  
Adrián de Santiago ◽  
Adriana Arvizu ◽  
Norma Gonzalez-Tableros ◽  
...  

The aim of the present study was to describe the association of positive flow cross match (FXM) and C1q-SAB.Methods. In this observational, cross-sectional, and comparative study, patients included had negative AHG-CDC-XM and donor specific antibodies (DSA) and were tested with FXM. All pretransplant sera were tested with C1q-SAB assay.Results. A total of 50 donor/recipient evaluations were conducted; half of them had at least one C1q+ Ab (n=26, 52%). Ten patients (20.0%) had DSA C1q+ Ab. Twenty-five (50%) FXMs were positive. Factors associated with a positive FXM were the presence of C1q+ Ab (DSA C1q+ Ab: OR 27, 2.80–259.56,P=0.004, and no DSA C1q+ Ab: OR 5, 1.27–19.68,P=0.021) and the DSA LABScreen-SAB MFI (OR 1.26, 95% CI 1.06–1.49,P=0.007). The cutoff point of immunodominant LABScreen SAB DSA-MFI with the greatest sensitivity and specificity to predict FXM was 2,300 (sensitivity: 72% and specificity: 75%). For FXM prediction, DSA C1q+ Ab was the most specific (95.8%, 85–100) and the combination of DSA-MFI > 2,300 and C1q+ Ab was the most sensitive (92.0%, 79.3–100).Conclusions. C1q+ Ab and LABScreen SAB DSA-MFI were significantly associated with FXM. DSA C1q+ Ab was highly specific but with low sensitivity.


2010 ◽  
Vol 90 ◽  
pp. 84 ◽  
Author(s):  
L. E. Morales-Buenrostro ◽  
S. A. Leyva ◽  
L. A. Marino-Vazquez ◽  
O. Vega-Vega ◽  
J. Alberú

Sign in / Sign up

Export Citation Format

Share Document